BeiGene, Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
233.25
+1.26 (0.54%)
At close: May 12, 2025, 4:00 PM
233.25
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
BeiGene Revenue
BeiGene had revenue of $1.12B in the quarter ending March 31, 2025, with 48.64% growth. This brings the company's revenue in the last twelve months to $4.18B, up 51.16% year-over-year. In the year 2024, BeiGene had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.18B
Revenue Growth
+51.16%
P/S Ratio
5.89
Revenue / Employee
$379,624
Employees
11,000
Market Cap
25.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ONC News
- 3 hours ago - Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + - Seeking Alpha
- 4 days ago - BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit - Seeking Alpha
- 5 days ago - BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat - Benzinga
- 5 days ago - BeiGene Announces First Quarter 2025 Financial Results and Business Updates - Business Wire
- 13 days ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 25 days ago - BeiGene to Announce First Quarter 2025 Financial Results on May 7 - Business Wire
- 5 weeks ago - BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit - Benzinga